



SHEET 1 OF 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Substitute for form 1449/PTO)

ATTY. DOCKET NO.
050229-0436

SERIAL NO.
10/830,089

APPLICANT
Craig JORDAN

FILING DATE
April 23, 2004

GROUP
1644

U.S. PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Document Number Number-Kind Code ₂ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	US				
	US				/
	US				/
	US				

FOREIGN PATENT DOCUMENTS

EXAMINER'S INITIALS	CITE NO.	Foreign Patent Document Country Codes-Number 4-Kind Codes (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Figures Appear	Translation Yes No

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER'S INITIALS	CITE NO.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	
/MB/		ROSENBLUM et al., "Recombinant Immunotoxins Directed against the c-erb-2/HER2/neu Oncogene Product: <i>In Vitro</i> Cytotoxicity, Pharmacokinetics, and <i>In Vivo</i> Efficacy Studies in Xenograft Models," Clinical Cancer Research, vol. 5, no. 4, April 1999, (1999-04), pp. 865-874, XP002312936	
/MB/		European Search Report issued in Patent Application No. 01 923 325.3-1222 dated on September 26, 2008	

EXAMINER

/Michail Belyavskyi/ (04/22/2009)

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.